Wang Yang, Gao Anju, Xu Xiang, Dang Baoqi, You Wanchun, Li Haiying, Yu Zhengquan, Chen Gang
Department of Neurosurgery, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, People's Republic of China.
Mol Neurobiol. 2015 Aug;52(1):64-77. doi: 10.1007/s12035-014-8846-y. Epub 2014 Aug 12.
α-Lipoic acid-plus (LAP), an amine derivative of α-lipoic acid (LA), could protect cells against oxidant challenges via chelating intralysosomal iron. However, the application of LAP in experimental subarachnoid hemorrhage (SAH) is still not well known. This study was designed to evaluate the potential neuroprotection of LAP on the early brain injury (EBI) and the underlying mechanisms in a rat model of SAH. The SAH models were induced in Sprague-Dawley rats. LA and LAP were oral administration and lasted for 72 h once a day. The brain tissue samples were obtained for assay at 72 h after SAH. In experiment 1, we found that lysosome amounts in neurons decreased significantly in SAH group, and LAP (100 mg/kg) could stabilize lysosomal membrane markedly based on lysosomal-associated membrane protein-1 (LAMP-1) expression in neurons by immunofluorescence. Hence, the LAP dosages of 100 and 150 mg/kg were applied in experiment 2. Firstly, Western blot analysis showed that the protein levels of cathepsin B/D, caspase-3, Bax, ferritin, and heme-oxygenase-1 (HO-1) markedly increased after SAH, which were further confirmed by double immunofluorescence staining and reversed by LA and LAP treatments. In addition, LA and LAP also reduced oxidative stress and iron deposition in brain tissue. Furthermore, LA and LAP significantly ameliorated brain edema, blood-brain barrier injury, cortical apoptosis, and neurological behavior impairment induced by SAH. Finally, it is noteworthy that LAP exerted more significant effects than LA on these parameters as described above. LAP probably exerted neuroprotective effects via targeting lysosomes and chelating intralysosomal iron in EBI post-SAH in rats.
α-硫辛酸加合物(LAP)是α-硫辛酸(LA)的一种胺衍生物,可通过螯合溶酶体内铁来保护细胞免受氧化剂的挑战。然而,LAP在实验性蛛网膜下腔出血(SAH)中的应用仍鲜为人知。本研究旨在评估LAP对SAH大鼠模型早期脑损伤(EBI)的潜在神经保护作用及其潜在机制。在Sprague-Dawley大鼠中诱导建立SAH模型。LA和LAP采用口服给药,每天一次,持续72小时。在SAH后72小时获取脑组织样本进行检测。在实验1中,我们发现SAH组神经元中的溶酶体数量显著减少,基于免疫荧光法检测神经元中溶酶体相关膜蛋白-1(LAMP-1)的表达,LAP(100mg/kg)可显著稳定溶酶体膜。因此,在实验2中应用了100mg/kg和150mg/kg的LAP剂量。首先,蛋白质免疫印迹分析表明,SAH后组织蛋白酶B/D、半胱天冬酶-3、Bax、铁蛋白和血红素加氧酶-1(HO-1)的蛋白水平显著升高,双重免疫荧光染色进一步证实了这一点,而LA和LAP处理可使其逆转。此外,LA和LAP还降低了脑组织中的氧化应激和铁沉积。此外,LA和LAP显著改善了SAH诱导的脑水肿、血脑屏障损伤、皮质细胞凋亡和神经行为障碍。最后,值得注意的是,LAP在上述参数上比LA发挥了更显著的作用。LAP可能通过靶向溶酶体和螯合大鼠SAH后EBI中的溶酶体内铁发挥神经保护作用。